Extraintestinal manifestations of inflammatory bowel disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ricart E, Panaccione R, Loftus EV, et al.: Autoimmune disorders and extraintestinal manifestations in first degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004, 10:207–214.
Greenstein AJ, Janowitz HD, Sachar DB: The extraintestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976, 55:401–412.
Bernstein CN, Wajda A, Blanchard JF: The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005, 129:827–836.
Cappell MS, Turkieh A: Chronic pericarditis and pericardial tamponade associated with ulcerative colitis. Dig Dis Sci 2008, 53:149–154.
Watanabe T: Parotitis and acute pancreatitis in a patient with ulcerative colitis. Eur J Pediatr 2008, 167:945.
Mahid SS, Mulhall AM, Gholson RD, et al.: Inflammatory bowel disease and African Americans: a systematic review. Inflamm Bowel Dis 2008, 14:960–967.
Nguyen GC, Torres EA, Regueiro M, et al.: Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 2006, 101:1012–1023.
Basu D, Lopez I, Kulkarni A, Sellin JH: Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol 2005, 100:2254–2261.
Rodriguez VE, Costas PJ, Vazquez M, et al.: Prevalence of spondyloarthropathy in Puerto Rican patients with inflammatory bowel disease. Ethn Dis 2008, 18(Suppl 2):225–229.
Lanna CC, Ferrari M, Rocha SL, et al.: A cross-sectional study of 130 Brazilian patients with Crohn’s disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol 2008, 27:503–509.
Orchard TR, Thiyagaraja S, Welsh KI, et al.: Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000, 118:274–278.
Orchard TR, Chua CN, Ahmad T, et al.: Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002, 123:714–718.
Roussomoustakaki M, Satsangi J, Welsh K, et al.: Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997, 112:1845–1853.
Williams HRT, Sato H, Welsh KI, et al.: Clinical and genetic associations of pyoderma gangrenosum in patients with inflammatory bowel disease: evidence for a shared predisposition to extraintestinal manifestations [abstract]. Gut 2007, 56(Suppl III):A21. Presented at United European Gastroenterology Week. Paris; October 2007.
Peeters H, Vander Cruyssen B, Laukens D, et al.: Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn’s disease. Ann Rheum Dis 2004, 63:1131–1134.
Peeters H, Vander Cruyssen B, Mielants H, et al.: Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. J Gastroenterol Hepatol 2008, 23:132–137.
Mielants H, Veys EM, De Vos M, et al.: The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995, 22:2266–2272.
Elewaut D, De Keyser F, Van Den Bosch F, et al.: Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol 1998, 25:1932–1937.
Orchard TR, Wordsworth BP, Jewell DP: Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42:387–391.
Travis SP, Stange EF, Lémann M, et al.; European Crohn’s and Colitis Organisation: European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006, 55(Suppl 1):i16–i35.
Fornaciari G, Salvarini C, Beltrami M, et al.: Musculoskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001, 15:399–403.
Steer S, Jones H, Hibbert J, Kondeatis, et al.: Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol 2003, 30:518–522.
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, et al.: Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis 1978, 37:33–35.
Brown MA, Pile KD, Kennedy LG, et al.: HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996, 55:268–270.
Orchard T, Holt H, Bradley L, et al.: Prevalence of sacroiliitis in Crohn’s disease, and its correlation with clinical, radiologic and genotypic parameters [abstract]. Gastroenterology 2002, 122(Suppl 4):W1298.
Thjodleifsson B, Geirsson AJ, Björnsson S, Bjarnason I: A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum 2007, 56:2633–2639.
Rahman P, Inman RD, Gladman DD, et al.: Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008, 58:1020–1025.
Duerr RH, Taylor KD, Brant SR, et al.: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461–1463.
Cargill M, Schrodi SJ, Chang M, et al.: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80:273–290.
Felder JB, Korelitz BI, Rajapakse R, et al.: Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000, 95:1949–1954.
Evans JM, McMahon AD, Murray FE, et al.: Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997, 40:619–622.
Takeuchi K, Smale S, Premshand P, et al.: Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:196–202.
Bonner GF, Fakhri A, Vennamaneni SR: A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:751–757.
Dougados M, Dijkmans B, Khan M, et al.: Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002, 61:40–50.
Chen J, Liu C, Lin J: Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006, CD004524.
Clegg DO, Reda DJ, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42:2325–2329.
Dougados M, van der Linden S, Leirisalo-Repo M, et al.: Sulfasalazine in the treatment of spondyloarthropathy. A randomised, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618–627.
Taggart A, Gardiner P, McEvoy F, et al.: Which is the active moiety of sulfasalazine in ankylosing spondylitis? Arthritis Rheum 1996, 39:1400–1405.
van Denderen JC, van der Horst-Bruinsma I, Bezemer PD, Dijkmans BA: Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J Rheumatol 2003, 30:1558–1560.
Thomson GT, Thomson BR, Thomson KS, Ducharme JS: Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol 2000, 27:714–718.
Dekker-Saeys BJ, Dijkmans BA, Tytgat GN: Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial. J Rheumatol 2000, 27:723–726.
Karimi O, Peña AS: Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary. Rev Esp Enferm Dig 2005, 97:570–574.
Levine JB, Lukawski-Trubish D: Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Amer 1995, 24:633–646.
Generini S, Giacomelli R, Fedi R, et al.: Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004, 63:1664–1669.
Braun J, Baraliakos X, Listing J, et al.: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007, 57:639–647.
Timani S, Mutasim DF: Skin manifestations of inflammatory bowel disease. Clin Dermatol 2008, 26:265–273.
Veloso FT, Carvalho J, Magro F: Immune-related systemic manifestations of inflammatory bowel disease: a prospective study of 792 patients. J Clin Gastroenterol 1996, 23:29–34.
Trost LB, McDonnell JK: Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005, 81:580–585.
Tavarela Veloso F: Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(Suppl 4):50–53.
Brooklyn T, Dunnill G, Probert C: Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006, 333:181–184.
Brooklyn TN, Dunnill MG, Shetty A, et al.: Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55:505–509.
Girardin M, Waschke KA, Seidman EG: A case of acute loss of vision as the presenting symptom of Crohn’s disease. Nat Clin Pract Gastroenterol Hepatol 2007, 4:695–698.
Mintz R, Feller ER, Bahr RL, Shah SA: Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:135–139.
Loftus EV: Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr Gastroenterol Rep 2004, 6:506–513.
Hale S, Lightman S: Anti-TNF therapies in the treatment of acute and chronic uveitis. Cytokine 2006, 33:231–237.
Moff SL, Kamel IR, Eustace J, et al.: Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006, 64:219–223.
Talwalkar JA, Angulo P, Johnson CD, et al.: Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004, 40:39–45.
Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691–695.
Mitchell SA, Bansi DA, Hunt N, et al.: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900–907.
Olsson R, Boberg KM, de Muckadell OS, et al.: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464–1472.
Cullen SN, Chapman RW: Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 21:933–948.
Brandsaeter B, Isoniemi H, Broome U, et al.: Liver transplantation for primary sclerosing cholangitis: predictors and consequences of hepatobiliary malignancy. J Hepatol 2004, 40:815–822.
Eaden JA, Mayberry JF: Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002, 51:v10–v12.
Wolf JM, Rybicki LA, Lashner BA: The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005, 22:783–788.
Pardi DS, Loftus EV, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889–893.
Rodríguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK: Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol 2007, 13:6156–6165.
Lamb EJ, Wong T, Smith DJ, et al.: Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1895–1902.
Card T, West J, Hubbard R, Logan RF: Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004, 53:251–255.
Vestergaard P, Mosekilde L: Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002, 156:1–10.
Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795–841
American Gastroenterological Association: Medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:791–794.
Boonen S, Rizzoli R, Meunier PJ, et al.: The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 2004, 15:511–519.
Henderson S, Hoffman N, Prince RA: Double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006, 101:119–123.
Raj AA, Birring SS, Green R, et al.: Prevalence of inflammatory bowel disease in patients with airways disease. Respir Med 2008, 102:780–785.
Izzedine H, Simon J, Piette AM, et al.: Primary chronic interstitial nephritis in Crohn’s disease. Gastroenterology 2002, 123:1436–1440.
Marcus SB, Brown JB, Melin-Aldana H, Strople JA: Tubulointerstitial nephritis: an extraintestinal manifestation of Crohn disease in children. J Pediatr Gastroenterol Nutr 2008, 46:338–341.
Baumer P, Brocard JF, Kohn W, et al.: Severe chronic interstitial nephritis associated with Crohn’s disease, but not with mesalazine? Gastroenterol Clin Biol 1999, 23:1400–1402.
Unal A, Sipahioglu MH, Akgun H, et al.: Crohn’s disease complicated by granulomatous interstitial nephritis, choroidal neovascularization, and central retinal vein occlusion. Intern Med 2008, 47:103–107.